Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level

By P. Loehrer. 2007

831 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/50f6d5431db30d0770a03f9442eb9ecec0c8ce6e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Z. Goodman

In Hepatology

1. Z. Goodman

Citations in the corpus

• Long‐term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B (2010, background): “3% in patients with HBV DNA levels <300 copies/mL to approximately 15% when the HBV DNA level was >10(6) copies/mL.(2) Finally, all-cause and chronic liver disease mortality also increased with increasing HBV DNA levels.”
• Entecavir treatment for up to 5 years in patients with hepatitis B e antigen–positive chronic hepatitis B (2010, background): “The reasons for treatment discontinuation were: completion of treatment in the opinion of the investigator (12), progression of CHB (1); death (5); loss to follow-up (2); patient noncompliance (1); withdrawal of consent (14); minimal virologic response (3); and other (9).”